<DOC>
	<DOCNO>NCT00417378</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety leave ventricular assist device comparison standard treatment intraaortic balloon pump ( IABP ) patient cardiogenic shock due leave ventricular failure follow acute coronary syndrome ( myocardial infarction ) .</brief_summary>
	<brief_title>Efficacy Study LV Assist Device Treat Patients With Cardiogenic Shock ( ISAR-SHOCK )</brief_title>
	<detailed_description>Cardiogenic shock due leave ventricular failure myocardial infarction ( MI ) associate mortality rate 50-70 % despite effort immediate PCI occlude vessel , positive inotropic drug , use intraaortic balloon counterpulsation ( IABP ) . While urgent heart transplantation surgical implantation high-volume leave ventricular assist device possible treatment option , widespread use technique common complication myocardial infarction limit . Because easy , percutaneous use intraaortic balloon pump , IABP method choice mechanical assistance patient . Despite lack randomized data , ACC/AHA guideline recommend use intraaortic balloon counterpulsation ( Level evidence IB ) patient cardiogenic shock myocardial infarction . However , improvement hemodynamic state use IABP limit lack active cardiac support remain major limitation treatment . Percutaneous leave ventricular assist device may overcome limitation surgical approach offer potential benefit active cardiac support recovery failing leave ventricle PCI . Previous study demonstrate significant improvement hemodynamic parameter use catheter-based miniaturized rotary blood pump ( Impella LP2.5 , Abiomed-Impella CardioSystems GmbH , Aachen , Germany ) , place retrogradely aortic valve . The microaxial pump aspirate blood leave ventricle expels ascend aorta maximal flow 2.5 L/min . Randomized data comparing LVAD IABP miss . Therefore , trial primarily compare hemodynamic improvement LVAD ( Impella LP2.5 ) hemodynamic improvement intraaortic balloon counterpulsation ( IABP ) , secondarily feasibility , safety mortality compare .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Cardiogenic</mesh_term>
	<criteria>Acute coronary syndrome ( ACS/AMI ) &lt; 48h cardiogenic shock define : Clinical criterion : Hypotension ( syst.BP &lt; 90 mmHg HR &gt; 90/min AV Block IIIII ) need positive inotropic drug maintain BB &gt; 90mm Hg ) endorgan hypoperfusion Hemodynamic criterion : CI &lt; 2.2 L/min/qm PCWP &gt; 15 mmHg EF LV &lt; 30 % LVEDP &gt; 20 mmHg . Written informed consent patient his/hers relatives Age &lt; 18 year Prolonged Resuscitation ( &gt; 30min ) Hypertrophic Obstructive Cardiomyopathy Thrombus leave ventricle Treatment IABP Severe valvular disease mechanical heart valve Cardiogenic Shock due mechanical complication myocardial infarction VSD , acute mitral regurgitation &gt; II° , rupture ventricle Failure right ventricle define need RV Assist Device Septic condition Cerebral Disease Bleeding need surgical intervention Pulmonary embolism Allergy Heparin know coagulopathy Aortic regurgitation &gt; II° Pregnancy Inclusion another study trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>ACS</keyword>
</DOC>